IGM Biosciences (NASDAQ:IGMS) Given New $11.00 Price Target at HC Wainwright

IGM Biosciences (NASDAQ:IGMS – Free Report) had its price objective decreased by HC Wainwright from $12.00 to $11.00 in a report issued on Thursday morning, Benzinga reports. HC Wainwright currently has a neutral rating on the stock. A number of other brokerages also recently weighed in on IGMS. Truist Financial lowered their price target on […]

Leave a Reply

Your email address will not be published.

Previous post Barclays Raises Credo Technology Group (NASDAQ:CRDO) Price Target to $32.00
Next post MercadoLibre (NASDAQ:MELI) Now Covered by Cantor Fitzgerald